NCT00052572View on ClinicalTrials.gov

Ixabepilone in Treating Patients With Relapsed or Refractory Lymphoproliferative Disorders

PHASE2CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

October 31, 2002

Study Completion Date

July 31, 2007

Conditions
LeukemiaLymphoma
Interventions
DRUG

ixabepilone

Trial Locations (2)

10021

Memorial Sloan-Kettering Cancer Center, New York

05401-3498

Vermont Cancer Center at University of Vermont, Burlington

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00052572 - Ixabepilone in Treating Patients With Relapsed or Refractory Lymphoproliferative Disorders | Biotech Hunter | Biotech Hunter